KalVista Pharmaceuticals, Inc. financial data

Symbol
KALV on Nasdaq
Industry
Pharmaceutical Preparations
Location
55 Cambridge Parkway, Suite 901 E, Cambridge, MA
State of incorporation
DE
Fiscal year end
April 30
Former names
Carbylan Therapeutics, Inc. (to 11/21/2016), Carbylan Biosurgery, Inc (to 1/3/2013), Carbylan Biosurgery Inc (to 12/29/2005)
Latest financial report
10-K - Q1 2024 - Jul 11, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 824 % -42.7%
Return On Equity -92.3 % -62.4%
Return On Assets -78.1 % -53.8%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 42.7M shares +24.8%
Common Stock, Shares, Outstanding 42.5M shares +24.4%
Entity Public Float 273M USD +128%
Common Stock, Value, Issued 42K USD +23.5%
Weighted Average Number of Shares Outstanding, Basic 36.8M shares +31.9%
Weighted Average Number of Shares Outstanding, Diluted 36.8M shares +31.9%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 86.2M USD +7.34%
General and Administrative Expense 54.3M USD +77.4%
Operating Income (Loss) -140M USD -26.7%
Nonoperating Income (Expense) 13.8M USD -23.2%
Net Income (Loss) Attributable to Parent -127M USD -36.3%
Earnings Per Share, Basic -3.44 USD/shares -3.3%
Earnings Per Share, Diluted -3.44 USD/shares -3.3%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 31.8M USD -43.5%
Assets, Current 226M USD +31%
Property, Plant and Equipment, Net 2.23M USD -24.5%
Operating Lease, Right-of-Use Asset 6.92M USD -11.5%
Other Assets, Noncurrent 567K USD +435%
Assets 235M USD +28.5%
Accounts Payable, Current 9.11M USD +89.1%
Employee-related Liabilities, Current 6.69M USD +58.9%
Accrued Liabilities, Current 12.4M USD +35.8%
Liabilities, Current 22.8M USD +51.7%
Operating Lease, Liability, Noncurrent 6.02M USD -15.8%
Accumulated Other Comprehensive Income (Loss), Net of Tax -3.49M USD -14%
Retained Earnings (Accumulated Deficit) -470M USD -36.9%
Stockholders' Equity Attributable to Parent 207M USD +28.3%
Liabilities and Equity 235M USD +28.5%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -26.7M USD -17.5%
Net Cash Provided by (Used in) Financing Activities 204K USD +21.4%
Net Cash Provided by (Used in) Investing Activities 19.6M USD -34.7%
Common Stock, Shares Authorized 100M shares 0%
Common Stock, Shares, Issued 42.5M shares +24.4%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -6.83M USD -196%
Deferred Tax Assets, Valuation Allowance 58.5M USD +29.3%
Deferred Tax Assets, Gross 60M USD +27.5%
Operating Lease, Liability 7.32M USD -11.1%
Payments to Acquire Property, Plant, and Equipment 6K USD -99.3%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -127M USD -38%
Lessee, Operating Lease, Liability, to be Paid 8.99M USD -14.7%
Property, Plant and Equipment, Gross 5.94M USD +0.56%
Operating Lease, Liability, Current 1.3M USD +19.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 1.9M USD +2.82%
Lessee, Operating Lease, Liability, to be Paid, Year One 1.87M USD +7.55%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 1.68M USD -27.5%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.85M USD +4.35%
Deferred Tax Assets, Operating Loss Carryforwards 50.2M USD +40.2%
Unrecognized Tax Benefits 0 USD
Lessee, Operating Lease, Liability, to be Paid, Year Four 1.87M USD +3.37%
Depreciation, Depletion and Amortization 193K USD +22.2%
Deferred Tax Assets, Net of Valuation Allowance 1.43M USD -18.8%
Share-based Payment Arrangement, Expense 3.25M USD +23.2%